New Releases from NCBI BookshelfPasireotide (Signifor LAR): Therapeutic area: Acromegaly, adults: Reimbursement Review [Internet].Pasireotide (Signifor LAR): Therapeutic area: Acromegaly, adults: Reimbursement Review [Internet].
Post Content
December 30, 2025
Uncategorized
New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ≥ 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy: Reimbursement Recommendation [Internet].Pembrolizumab (Keytruda): Indication: For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ≥ 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Keytruda should be reimbursed by public drug plans for the treatment of adult patients
Uncategorized
New Releases from NCBI BookshelfCabozantinib: Therapeutic area: Neuroendocrine tumours: Reimbursement Review [Internet].Cabozantinib: Therapeutic area: Neuroendocrine tumours: Reimbursement Review [Internet].
Neuroendocrine tumours (NETs), including extrapancreatic (epNET) and pancreatic (pNET) types, originate from secretory cells and can occur in various organs.
Uncategorized
New Releases from NCBI BookshelfQuetiapine for Bipolar Disorder: Drugs [Internet].Quetiapine for Bipolar Disorder: Drugs [Internet].
Quetiapine, among other antipsychotics, could be used as a first-line treatment option for the management of bipolar disorder in adults.
Uncategorized
New Releases from NCBI BookshelfMirvetuximab Soravtansine (Elahere): Indication: As monotherapy indicated for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens: Reimbursement Recommendation [Internet].Mirvetuximab Soravtansine (Elahere): Indication: As monotherapy indicated for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Elahere be reimbursed by public drug plans for the treatment of adults with FR-alpha–positive,
